Our proprietary technology focus on the dual functions of pentamidine on controlling the function of a DNA repair enzyme – endo-exonuclease (EE:Trmt2) and specific targets anti-inflammatory/Lipopolysaccharide (LPS) binding.
The EE is found in large amounts in cancer cells and its function is to repair DNA breaks that occur when cancer cells proliferate. Blocking this enzyme would cut off cancer growth. With a unique combination of proprietary expertise on EE (Trmt2) and pentamidine, the company is well positioned to develop pentamidine analogs for breakthrough solutions in cancer therapy1-5. Pentamidine is known to be active on cancer cells. The effectiveness and significance of DNA repair process in medicine has most recently been exemplified in 2015 Nobel Prize in Chemistry.
The effect of pentamidine as potential anti-inflammatory agent is well documented6,7. However, its development for anti-inflammation application is limited by its cytotoxic effect. With proprietary technology, we are able to identify pentamidine analogs that retains the anti-inflammation activity but reduce cytotoxicity to broaden our scope into Gastro-intestine (GI) condition as well as liver disease.
Company Details
- Employees
- 1
- Address
- 5760 Avenue Royalmount, Suite 101,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.montdorex.com
- HQ
- Mont-Royal, Quebec
Montdorex Questions
Montdorex's website is http://www.montdorex.com
Montdorex's LinkedIn profile is https://ca.linkedin.com/company/montdorex
Montdorex has
1 employees.
View email and phone details for 1
employees at Montdorex.
Montdorex's industry is
Biotechnology Research
Montdorex's top competitors are
Knight Therapeutics,
Cyclenium Pharma Inc.,
Aeroflux,
Butler Asia,
Wada Foodtech,
I-Rna Corporation,
Luquos Energy,
Giiant Pharma Inc.,
Theratechnologies Inc.,
Pharmascience.
Montdorex's categories are Biotechnology Research
